Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers

Prostate cancer is a complex disease that necessitates precise evaluation and treatment decisions dependent on cancer stage and aggressiveness. Nonetheless, existing methods have limitations in capturing the complete range of prostate cancer behavior and progression. Although methods such as the his...

Full description

Saved in:
Bibliographic Details
Main Authors: Matteo Villa, Giorgio Cazzaniga, Maddalena Bolognesi, Federica Malighetti, Valentina Crippa, Andrea Aroldi, Giorgio Bozzini, Fabio Pagni, Rocco Piazza, Luca Mologni, Daniele Ramazzotti
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402501919X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849319592648769536
author Matteo Villa
Giorgio Cazzaniga
Maddalena Bolognesi
Federica Malighetti
Valentina Crippa
Andrea Aroldi
Giorgio Bozzini
Fabio Pagni
Rocco Piazza
Luca Mologni
Daniele Ramazzotti
author_facet Matteo Villa
Giorgio Cazzaniga
Maddalena Bolognesi
Federica Malighetti
Valentina Crippa
Andrea Aroldi
Giorgio Bozzini
Fabio Pagni
Rocco Piazza
Luca Mologni
Daniele Ramazzotti
author_sort Matteo Villa
collection DOAJ
description Prostate cancer is a complex disease that necessitates precise evaluation and treatment decisions dependent on cancer stage and aggressiveness. Nonetheless, existing methods have limitations in capturing the complete range of prostate cancer behavior and progression. Although methods such as the histological assessment of the Gleason score provide a valuable approximation of cancer behavior, understanding the fundamental mechanisms of each neoplasm and effectively translating this knowledge into clinical practice present challenges that can impact treatment approaches.Here, we perform a comprehensive analysis of large-scale multi-omics datasets from The Cancer Genome Atlas and other studies, aiming to unravel the molecular and clinical features underlying prostate cancer progression. Using an integrative clustering approach, we determine distinct molecular subtypes associated with potential prognostic biomarkers. Through computational validation in independent cohorts, we reinforce their potential for molecular subtyping, demonstrating the clinical significance of the hypothesized markers. To evaluate the clinical impact of these biomarkers, we perform immunohistochemistry assays on patient samples, confirming their prognostic potential. Among the investigated biomarkers, CCNB1, FOXM1, and RAD51 emerged as the most promising candidates for prognostic evaluation.The results validate the utility of these biomarkers, bridging the gap between bioinformatics analyses and experimental validation. This study expands our understanding of prostate cancer progression through comprehensive multi-omics analyses. The identification and validation of molecular subtypes for the identification of potential prognostic biomarker offers valuable insights for improved treatment decisions and personalized care in prostate cancer. These findings provide a foundation for future investigations and pave the way for the development of targeted therapeutic approaches in prostate cancer management.
format Article
id doaj-art-12a0e7fbb1d7499783337f0f3a8e3e94
institution Kabale University
issn 2405-8440
language English
publishDate 2025-07-01
publisher Elsevier
record_format Article
series Heliyon
spelling doaj-art-12a0e7fbb1d7499783337f0f3a8e3e942025-08-20T03:50:22ZengElsevierHeliyon2405-84402025-07-011112e4353310.1016/j.heliyon.2025.e43533Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkersMatteo Villa0Giorgio Cazzaniga1Maddalena Bolognesi2Federica Malighetti3Valentina Crippa4Andrea Aroldi5Giorgio Bozzini6Fabio Pagni7Rocco Piazza8Luca Mologni9Daniele Ramazzotti10Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Corresponding authors.Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Department of Medicine and Surgery, Pathology, IRCCS Fondazione San Gerardo dei Tintori, University of Milano-Bicocca, Italy; Corresponding author. Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy.Department of Medicine and Surgery, University of Milano-Bicocca, Milano, ItalyDepartment of Medicine and Surgery, University of Milano-Bicocca, Milano, ItalyDepartment of Medicine and Surgery, University of Milano-Bicocca, Milano, ItalyDepartment of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Hematology and Clinical Research Unit, San Gerardo Hospital, Monza, ItalyHospital ASST Lariana, Como, ItalyDepartment of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Department of Medicine and Surgery, Pathology, IRCCS Fondazione San Gerardo dei Tintori, University of Milano-Bicocca, ItalyDepartment of Medicine and Surgery, University of Milano-Bicocca, Milano, ItalyDepartment of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Corresponding authors.Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Corresponding author.Prostate cancer is a complex disease that necessitates precise evaluation and treatment decisions dependent on cancer stage and aggressiveness. Nonetheless, existing methods have limitations in capturing the complete range of prostate cancer behavior and progression. Although methods such as the histological assessment of the Gleason score provide a valuable approximation of cancer behavior, understanding the fundamental mechanisms of each neoplasm and effectively translating this knowledge into clinical practice present challenges that can impact treatment approaches.Here, we perform a comprehensive analysis of large-scale multi-omics datasets from The Cancer Genome Atlas and other studies, aiming to unravel the molecular and clinical features underlying prostate cancer progression. Using an integrative clustering approach, we determine distinct molecular subtypes associated with potential prognostic biomarkers. Through computational validation in independent cohorts, we reinforce their potential for molecular subtyping, demonstrating the clinical significance of the hypothesized markers. To evaluate the clinical impact of these biomarkers, we perform immunohistochemistry assays on patient samples, confirming their prognostic potential. Among the investigated biomarkers, CCNB1, FOXM1, and RAD51 emerged as the most promising candidates for prognostic evaluation.The results validate the utility of these biomarkers, bridging the gap between bioinformatics analyses and experimental validation. This study expands our understanding of prostate cancer progression through comprehensive multi-omics analyses. The identification and validation of molecular subtypes for the identification of potential prognostic biomarker offers valuable insights for improved treatment decisions and personalized care in prostate cancer. These findings provide a foundation for future investigations and pave the way for the development of targeted therapeutic approaches in prostate cancer management.http://www.sciencedirect.com/science/article/pii/S240584402501919XProstate cancerMulti-omics analysisMolecular subtypesPrognostic biomarkersPersonalized medicine
spellingShingle Matteo Villa
Giorgio Cazzaniga
Maddalena Bolognesi
Federica Malighetti
Valentina Crippa
Andrea Aroldi
Giorgio Bozzini
Fabio Pagni
Rocco Piazza
Luca Mologni
Daniele Ramazzotti
Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
Heliyon
Prostate cancer
Multi-omics analysis
Molecular subtypes
Prognostic biomarkers
Personalized medicine
title Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
title_full Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
title_fullStr Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
title_full_unstemmed Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
title_short Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers
title_sort integrative multi omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis associated candidate biomarkers
topic Prostate cancer
Multi-omics analysis
Molecular subtypes
Prognostic biomarkers
Personalized medicine
url http://www.sciencedirect.com/science/article/pii/S240584402501919X
work_keys_str_mv AT matteovilla integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT giorgiocazzaniga integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT maddalenabolognesi integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT federicamalighetti integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT valentinacrippa integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT andreaaroldi integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT giorgiobozzini integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT fabiopagni integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT roccopiazza integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT lucamologni integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers
AT danieleramazzotti integrativemultiomicsanalysisenablesacomprehensivecharacterizationofprostatecancerandunveilsmetastasisassociatedcandidatebiomarkers